Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBS2418 Plus STRIDE in Advanced Unresectable Hepatocellular Carcinoma
NCT07175441Phase 2Recruiting
- Sponsor
- Riboscience LLC
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of rbs2418 in hepatocellular carcinoma (HCC), sponsored by Riboscience LLC. Started Apr 2026; status: recruiting.
02
Drugs
rbs2418
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07175441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175441.